RT Journal Article
SR Electronic
T1 Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression
JF Life Science Alliance
JO Life Sci. Alliance
FD Life Science Alliance LLC
SP e202000955
DO 10.26508/lsa.202000955
VO 4
IS 2
A1 André F Rendeiro
A1 Joseph Casano
A1 Charles Kyriakos Vorkas
A1 Harjot Singh
A1 Ayana Morales
A1 Robert A DeSimone
A1 Grant B Ellsworth
A1 Rosemary Soave
A1 Shashi N Kapadia
A1 Kohta Saito
A1 Christopher D Brown
A1 JingMei Hsu
A1 Christopher Kyriakides
A1 Steven Chiu
A1 Luca Vincenzo Cappelli
A1 Maria Teresa Cacciapuoti
A1 Wayne Tam
A1 Lorenzo Galluzzi
A1 Paul D Simonson
A1 Olivier Elemento
A1 Mirella Salvatore
A1 Giorgio Inghirami
YR 2021
UL https://www.life-science-alliance.org/content/4/2/e202000955.abstract
AB With a rising incidence of COVID-19–associated morbidity and mortality worldwide, it is critical to elucidate the innate and adaptive immune responses that drive disease severity. We performed longitudinal immune profiling of peripheral blood mononuclear cells from 45 patients and healthy donors. We observed a dynamic immune landscape of innate and adaptive immune cells in disease progression and absolute changes of lymphocyte and myeloid cells in severe versus mild cases or healthy controls. Intubation and death were coupled with selected natural killer cell KIR receptor usage and IgM+ B cells and associated with profound CD4 and CD8 T-cell exhaustion. Pseudo-temporal reconstruction of the hierarchy of disease progression revealed dynamic time changes in the global population recapitulating individual patients and the development of an eight-marker classifier of disease severity. Estimating the effect of clinical progression on the immune response and early assessment of disease progression risks may allow implementation of tailored therapies.